Kadmon Corporation

Kadmon Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company was founded in 2010 by Sam Waksal, who previously founded ImClone Systems, a biopharmaceutical company that was sold to Eli Lilly and Company in 2008.

History

Kadmon Corporation was established in 2010 by Sam Waksal. The company's initial focus was on the development of small molecules and biologics in the areas of oncology, immunology, and infectious disease. In 2016, Kadmon Corporation went public, trading on the New York Stock Exchange under the ticker symbol "KDMN".

Research and Development

Kadmon Corporation's research and development efforts are primarily focused on the areas of oncology, immunology, and infectious disease. The company's lead product candidate, KD025, is a ROCK2 inhibitor that is currently in Phase 2 clinical trials for the treatment of chronic graft-versus-host disease (cGVHD) and systemic sclerosis. Other product candidates in Kadmon's pipeline include KD033, an anti-PD-L1/IL-15 fusion protein, and KD045, a ROCK inhibitor for the treatment of fibrotic diseases.

Financials

As a publicly traded company, Kadmon Corporation's financial performance is reported on a quarterly and annual basis. The company's revenue primarily comes from product sales, licensing agreements, and research collaborations.

Criticism and Controversy

Kadmon Corporation has faced criticism and controversy, particularly in relation to its founder, Sam Waksal. Waksal has a history of legal troubles, including a conviction for insider trading while at ImClone Systems. Despite these controversies, Kadmon Corporation continues to operate and pursue its research and development goals.

See Also

• Biopharmaceutical
• Sam Waksal
• ImClone Systems
• Eli Lilly and Company
• New York Stock Exchange
• ROCK2 inhibitor
• Chronic graft-versus-host disease
• Systemic sclerosis
• Fibrotic diseases

References

‎